Table 1.
Study population characteristics
|
All participants |
Participants tested by PCR during the outcome period |
||||
|---|---|---|---|---|---|
| n | % | n | % | ||
| All | 4 622 106 | 100% | 414 436 | 100% | |
| Sex | |||||
| Female | 2 342 608 | 50·7% | 226 222 | 54·6% | |
| Male | 2 279 498 | 49·3% | 188 214 | 45·4% | |
| Age, years | |||||
| 18–24 | 482 695 | 10·4% | 30 543 | 7·4% | |
| 25–34 | 746 790 | 16·2% | 59 735 | 14·4% | |
| 35–44 | 663 542 | 14·4% | 51 806 | 12·5% | |
| 45–54 | 768 454 | 16·6% | 68 988 | 16·7% | |
| 55–64 | 763 964 | 16·5% | 78 874 | 19·0% | |
| 65–74 | 624 590 | 13·5% | 61 873 | 14·9% | |
| 75–84 | 440 840 | 9·5% | 45 187 | 10·9% | |
| ≥85 | 131 231 | 2·8% | 17 430 | 4·2% | |
| Region of residency | |||||
| Capital | 1 451 806 | 31·4% | 150 372 | 36·3% | |
| Central Denmark | 1 052 396 | 22·8% | 80 397 | 19·4% | |
| Northern Denmark | 472 794 | 10·2% | 36 155 | 8·7% | |
| Zealand | 673 221 | 14·6% | 63 555 | 15·3% | |
| Southern Denmark | 971 563 | 21·0% | 83 957 | 20·3% | |
| Missing data | 326 | 0 | .. | .. | |
| Migration heritage* | |||||
| Denmark | 3 982 616 | 86·2% | 345 707 | 83·4% | |
| Other European country | 295 988 | 6·4% | 25 730 | 6·2% | |
| Middle East and north Africa | 166 071 | 3·6% | 21 304 | 5·1% | |
| Indian subcontinent and southeast Asia | 111 427 | 2·4% | 13 594 | 3·3% | |
| Sub-Saharan Africa | 37 342 | 0·8% | 4654 | 1·1% | |
| Other | 28 559 | 0·6% | 3447 | 0·8% | |
| Missing data | 103 | 0 | .. | .. | |
| Number of comorbidities† | |||||
| 0 | 3 659 772 | 79·2% | 297 644 | 71·8% | |
| 1 | 715 355 | 15·5% | 79 270 | 19·1% | |
| 2 | 186 128 | 4·0% | 26465 | 6·4% | |
| ≥3 | 60 802 | 1·3% | 11 057 | 2·7% | |
| Missing data | 47 | 0 | .. | .. | |
| COVID-19 vaccination status‡ | |||||
| Unvaccinated | 382 479 | 8·3% | 31 880 | 7·7% | |
| Primary vaccination with two mRNA doses completed | 38 558 | 0·8% | 4011 | 1·0% | |
| Primary non-mRNA vaccination completed | 5463 | 0·1% | 596 | 0·1% | |
| Primary mRNA vaccination completed plus one mRNA booster dose | 3 396 426 | 73·5% | 305 731 | 73·8% | |
| Primary non-mRNA vaccination completed plus one mRNA booster dose | 147 970 | 3·2% | 18 055 | 4·4% | |
| Primary vaccination completed plus two booster doses—any types | 36 465 | 0·8% | 6365 | 1·5% | |
| Other§ | 614 745 | 13·3% | 47 798 | 11·5% | |
| PCR-confirmed SARS-CoV-2 infection status by April 10, 2022 | |||||
| No previous infection | 2 457 297 | 53·2% | 256 449 | 61·9% | |
| At least one previous infection | 2 164 809 | 46·8% | 157 987 | 38·1% | |
| Infection likely to have been with omicron¶ | 1 685 557 | 77·9% | 111 047 | 70·3% | |
| Infection likely to have been with an earlier variant than omicron | 479 252 | 22·1% | 46 940 | 29·7% | |
Data are n or %. Participants were older than 18 years on April 10, 2022 and had been resident in Denmark since Feb 1, 2020.
Migration heritage was defined by country of birth or, if known, mother's country of birth.
Comorbidities registered during the past 5 years from among: diabetes, adiposity, haematological and other cancers, neurological diseases, kidney diseases, cardiovascular diseases, chronic pulmonary diseases, respiratory diseases, and immune deficiency conditions.
Vaccinations received by April 10, 2022; mRNA vaccines were either BNT162b2 (tozinameran, Pfizer-BioNtech) or mRNA-1273 (lasomeran, Moderna); non-mRNA vaccines were Jcovden (previously COVID-19 Vaccine Janssen) and ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca).
Incomplete primary vaccination series or non-mRNA vaccine booster doses.
Infections likely to have been with omicron were those in people who tested positive for COVID-19 after Dec 20, 2021.